{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:59:31Z","timestamp":1791291571396,"version":"4.3.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.semarthrit.2012.03.014","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T02:03:01Z","timestamp":1335405781000},"page":"281-296","source":"Crossref","is-referenced-by-count":24,"title":["Potential Immunologic Targets for Treating Fibrosis in Systemic Sclerosis: A Review Focused on Leukocytes and Cytokines"],"prefix":"10.1016","volume":"42","author":[{"given":"Minoru","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00002281-200211000-00015","article-title":"Cytokine directed therapy in scleroderma: Rationale, current status, and the future","volume":"14","author":"Simms","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.it.2005.09.002","article-title":"Targeted therapy comes of age in scleroderma","volume":"26","author":"Denton","year":"2005","journal-title":"Trends Immunol"},{"issue":"9523","key":"10.1016\/j.semarthrit.2012.03.014_bib4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(06)68737-0","article-title":"Systemic sclerosis: Hypothesis-driven treatment strategies","volume":"367","author":"Charles","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: A prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2010.48","article-title":"Targeted therapy for systemic sclerosis: How close are we?","volume":"6","author":"Ramos-Casals","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BOR.0b013e328337c3d6","article-title":"Innovative therapies for systemic sclerosis","volume":"22","author":"Ong","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2169\/internalmedicine.41.608","article-title":"High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction","volume":"41","author":"Tyndall","year":"2002","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9790","key":"10.1016\/j.semarthrit.2012.03.014_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semarthrit.2007.10.010","article-title":"The immunobiology of systemic sclerosis","volume":"38","author":"Gu","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2556","article-title":"Garden of therapeutic delights: New targets in rheumatic diseases","volume":"11","author":"Waldburger","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"2-3","key":"10.1016\/j.semarthrit.2012.03.014_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12016-008-8114-x","article-title":"Recent advances in the treatment of systemic sclerosis","volume":"36","author":"Bournia","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2012.03.014_bib14","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases","volume":"69","author":"Furst","year":"2010","journal-title":"Ann Rheum Dis 2009"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1346-8138.2009.00758.x","article-title":"Future treatments in systemic sclerosis","volume":"37","author":"Asano","year":"2010","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1346-8138.2009.00738.x","article-title":"Mechanisms of skin fibrosis in systemic sclerosis","volume":"37","author":"Jinnin","year":"2010","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semarthrit.2009.09.003","article-title":"Is there a role for B-cell depletion as therapy for scleroderma?","volume":"40","author":"Daoussis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.autrev.2010.08.003","article-title":"Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis","volume":"10","author":"Baraut","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.it.2009.12.001","article-title":"The immunology of fibrosis: Innate and adaptive responses","volume":"31","author":"Wick","year":"2010","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","article-title":"Biologic therapy for systemic sclerosis: A systematic review","volume":"38","author":"Phumethum","year":"2011","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/BOR.0b013e32834b0dac","article-title":"An update on an immune system that goes awry in systemic sclerosis","volume":"23","author":"van Bon","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0b013e32833038ce","article-title":"Noncanonical transforming growth factor beta signaling in scleroderma fibrosis","volume":"21","author":"Trojanowska","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.it.2005.09.004","article-title":"Scleroderma: From cell and molecular mechanisms to disease models","volume":"26","author":"Abraham","year":"2005","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.21894","article-title":"Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts","volume":"54","author":"Gardner","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib26","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/jid.2010.15","article-title":"Antagonistic effect of the matricellular signaling protein CCN3 on TGF-beta- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome","volume":"130","author":"Lemaire","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/art.30312","article-title":"Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?","volume":"63","author":"Wei","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1136\/ard.2010.147140","article-title":"Inhibition of glycogen synthase kinase 3\u03b2 induces dermal fibrosis by activation of the canonical Wnt pathway","volume":"70","author":"Bergmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib29","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard.2010.134742","article-title":"Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis","volume":"70","author":"Dees","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib30","doi-asserted-by":"crossref","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","article-title":"PPAR\u03b3 downregulation by TGF\u03b2 in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib31","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2004.027094","article-title":"Early T cell activation in the skin from patients with systemic sclerosis","volume":"64","author":"Kalogerou","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib33","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1073\/pnas.0700021104","article-title":"Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13","volume":"104","author":"Aliprantis","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.23406","article-title":"T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease","volume":"58","author":"Boin","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib35","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.20315","article-title":"Is systemic sclerosis an antigen-driven T cell disease?","volume":"50","author":"Sakkas","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib36","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jdermsci.2008.01.001","article-title":"Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?","volume":"50","author":"Murata","year":"2008","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib38","doi-asserted-by":"crossref","first-page":"e5903","DOI":"10.1371\/journal.pone.0005903","article-title":"The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib40","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: Associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20092121","article-title":"Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent","volume":"207","author":"Wilson","year":"2010","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib42","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/rheumatology\/keq094","article-title":"Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?","volume":"49","author":"De Palma","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib43","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09633.x","article-title":"Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea","volume":"162","author":"Antiga","year":"2010","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116525","article-title":"Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma","volume":"70","author":"Klein","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib45","doi-asserted-by":"crossref","first-page":"e5981","DOI":"10.1371\/journal.pone.0005981","article-title":"Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2009.12.009","article-title":"Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity","volume":"261","author":"Slobodin","year":"2010","journal-title":"Cell Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2010.06.004","article-title":"Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis","volume":"137","author":"Giovannetti","year":"2010","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib48","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1073\/pnas.0900408106","article-title":"Identification of IL-17-producing FOXP3+ regulatory T cells in humans","volume":"106","author":"Voo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.semarthrit.2012.03.014_bib49","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1073\/pnas.0900621106","article-title":"Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t","volume":"106","author":"Ayyoub","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.semarthrit.2012.03.014_bib50","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1182\/blood-2008-10-183251","article-title":"IL-17-producing human peripheral regulatory T cells retain suppressive function","volume":"113","author":"Beriou","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/0961203310392431","article-title":"Elevated circulating CD4+ ICOS+ Foxp3+ T cells contribute to overproduction of IL-10 and are correlated with disease severity in patients with systemic lupus erythematosus","volume":"20","author":"Liu","year":"2011","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib52","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib53","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.27428","article-title":"Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator\/inducible costimulator ligand pathway","volume":"62","author":"Tanaka","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib54","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/ard.2007.073387","article-title":"Blockade of CD40\/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse","volume":"67","author":"Komura","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib55","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1002\/art.23994","article-title":"A CD40-CD154 interaction in tissue fibrosis","volume":"58","author":"Kawai","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"21","key":"10.1016\/j.semarthrit.2012.03.014_bib56","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib57","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis-associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib58","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ni0901-764","article-title":"Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity","volume":"2","author":"Lipsky","year":"2001","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib59","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib60","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib61","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib64","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.semarthrit.2012.03.014_bib66","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19\/CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.iy.13.040195.001015","article-title":"The CD19\/CR2\/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity","volume":"13","author":"Fearon","year":"1995","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib69","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib70","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.20674","article-title":"Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis","volume":"50","author":"Tsuchiya","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib71","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0039.2007.00801.x","article-title":"Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis","volume":"69","author":"Hitomi","year":"2007","journal-title":"Tissue Antigens"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib73","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib74","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","article-title":"CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma","volume":"172","author":"Yoshizaki","year":"2008","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib75","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/art.23995","article-title":"CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model","volume":"58","author":"Komura","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib76","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","article-title":"B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse","volume":"165","author":"Asano","year":"2004","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib77","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nri978","article-title":"Alternative activation of macrophages","volume":"3","author":"Gordon","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib79","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar3066","article-title":"Characterization of monocyte\/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis","volume":"12","author":"Higashi-Kuwata","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"10.1016\/j.semarthrit.2012.03.014_bib80","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1242\/jcs.02554","article-title":"Non-Smad TGF-beta signals","volume":"118","author":"Moustakas","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib81","first-page":"S691","article-title":"Anti-TGF beta 1 therapy for diffuse cutaneous systemic sclerosis: A multicenter, randomized, placebo-controlled Phase I\/II trial of cat-192","volume":"50","author":"Denton","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib82","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.0022-202X.2005.23859.x","article-title":"Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis","volume":"125","author":"Santiago","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib83","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3324\/haematol.12526","article-title":"CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis","volume":"93","author":"Campioni","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.yexmp.2006.12.003","article-title":"Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis","volume":"83","author":"Higashiyama","year":"2007","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib85","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/mol.105.017483","article-title":"Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression","volume":"69","author":"Jinnin","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib86","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ajpath.2011.01.035","article-title":"The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-beta that is up-regulated in systemic sclerosis and mediates profibrotic responses","volume":"178","author":"Fang","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib87","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/1523-1747.ep12363389","article-title":"Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor","volume":"107","author":"Frazier","year":"1996","journal-title":"J Invest Dermatol"},{"issue":"Suppl 5","key":"10.1016\/j.semarthrit.2012.03.014_bib88","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/rheumatology\/ken278","article-title":"Connective tissue growth factor: Growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?","volume":"47","author":"Abraham","year":"2008","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00002281-200111000-00010","article-title":"Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis","volume":"13","author":"Denton","year":"2001","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib90","first-page":"755","article-title":"Hypothesis: Pathogenesis of systemic sclerosis","volume":"30","author":"Takehara","year":"2003","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib91","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/art.24620","article-title":"Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen","volume":"60","author":"Ponticos","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/art.30074","article-title":"CCN2 is required for bleomycin-induced skin fibrosis in mice","volume":"63","author":"Liu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib93","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"25","key":"10.1016\/j.semarthrit.2012.03.014_bib94","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib95","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib96","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib97","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200404-531OC","article-title":"Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice","volume":"171","author":"Aono","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib98","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib99","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib100","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse systemic sclerosis: A single site trial","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib101","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one year space, phase I \/ IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib102","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib103","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib104","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.30171","article-title":"Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib105","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib106","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.23451","article-title":"Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma","volume":"58","author":"Duan","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib107","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: Association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib108","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar3221","article-title":"Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts","volume":"13","author":"Agarwal","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib109","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib110","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI111480","article-title":"Selective inhibition of human diploid fibroblast collagen synthesis by interferons","volume":"74","author":"Jimenez","year":"1984","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.semarthrit.2012.03.014_bib111","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1074\/jbc.M004709200","article-title":"Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta","volume":"276","author":"Ghosh","year":"2001","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib112","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI112945","article-title":"Gamma-interferon inhibits collagen synthesis in vivo in the mouse","volume":"79","author":"Granstein","year":"1987","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s004030000136","article-title":"Effect of interferon-gamma on experimental scleroderma induced by bleomycin","volume":"292","author":"Yamamoto","year":"2000","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.014_bib114","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.1780351005","article-title":"Treatment of systemic sclerosis with recombinant interferon-gamma","volume":"35","author":"Freundlich","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib115","first-page":"654","article-title":"A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: Effects on cutaneous fibrosis and interleukin 2 receptor levels","volume":"23","author":"Polisson","year":"1996","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib116","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1997.03890410065008","article-title":"Systemic scleroderma","volume":"133","author":"Hunzelmann","year":"1997","journal-title":"Arch Dermatol"},{"issue":"2 Suppl 65","key":"10.1016\/j.semarthrit.2012.03.014_bib117","first-page":"S40","article-title":"Is there a role for TNF\u03b1 antagonists in the treatment of SSc?","volume":"29","author":"Distler","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"17","key":"10.1016\/j.semarthrit.2012.03.014_bib118","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1073\/pnas.1737765100","article-title":"A nuclear target for interleukin-1alpha: Interaction with the growth suppressor necdin modulates proliferation and collagen expression","volume":"100","author":"Hu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib119","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI4304","article-title":"Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A","volume":"103","author":"Kawaguchi","year":"1999","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib120","first-page":"3786","article-title":"IL-1R1\/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice","volume":"117","author":"Gasse","year":"2007","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib121","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jcp.2004.019224","article-title":"Alterations of mononuclear inflammatory cells, CD4\/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis","volume":"58","author":"Hussein","year":"2005","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib122","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780350111","article-title":"Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma","volume":"35","author":"Needleman","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.014_bib123","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/art.22927","article-title":"Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis","volume":"56","author":"Parel","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib124","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","article-title":"Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis","volume":"42","author":"Atamas","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib125","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1073\/pnas.052709999","article-title":"Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts","volume":"99","author":"Kodera","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib126","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2619::AID-IMMU2619>3.0.CO;2-M","article-title":"Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma","volume":"28","author":"Ong","year":"1998","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib127","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1074-7613(00)80565-8","article-title":"TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype","volume":"8","author":"King","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1091\/mbc.4.6.637","article-title":"Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair","volume":"4","author":"Igarashi","year":"1993","journal-title":"Mol Biol Cell"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jcb.10144","article-title":"Interleukin-4 regulates connective tissue growth factor expression in human lung fibroblasts","volume":"85","author":"Rishikof","year":"2002","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.03.014_bib130","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib131","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.24432","article-title":"Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis","volume":"60","author":"Fuschiotti","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib132","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/art.30489","article-title":"GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production","volume":"63","author":"Medsger","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib133","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib134","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1165\/rcmb.2002-0009OC","article-title":"Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis","volume":"27","author":"Belperio","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib135","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.4049\/jimmunol.172.7.4068","article-title":"Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts","volume":"172","author":"Kolodsick","year":"2004","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.014_bib136","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib137","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib138","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/sj.jid.5700919","article-title":"BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice","volume":"127","author":"Matsushita","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib139","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib140","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib141","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.immuni.2011.03.005","article-title":"Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiationAutocrine transforming growth factor-\u03b21 promotes in vivo Th17 cell differentiation","volume":"34","author":"Gutcher","year":"2011","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib142","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.4049\/jimmunol.0901778","article-title":"Cell adhesion molecules regulate fibrotic process via Th1\/Th2\/Th17 cell balance in a bleomycin-induced scleroderma model","volume":"185","author":"Yoshizaki","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib143","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","article-title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib144","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"52","key":"10.1016\/j.semarthrit.2012.03.014_bib145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib146","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.4049\/jimmunol.0903306","article-title":"IL-33 induces IL-13-dependent cutaneous fibrosis","volume":"184","author":"Rankin","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib147","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.03.014_bib148","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.4049\/jimmunol.181.10.7243","article-title":"Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis","volume":"181","author":"Mozaffarian","year":"2008","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib149","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1002\/art.23134","article-title":"Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts","volume":"56","author":"Shi-wen","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib150","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.matbio.2007.06.003","article-title":"Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts","volume":"26","author":"Shi-Wen","year":"2007","journal-title":"Matrix Biol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib151","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib152","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/keq077","article-title":"Effect of bosentan on skin fibrosis in patients with systemic sclerosis: A prospective, open-label, non-comparative trial","volume":"49","author":"Kuhn","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib153","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/039463201002300422","article-title":"Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: An open-label, observational, retrospective study","volume":"23","author":"Giordano","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6776","key":"10.1016\/j.semarthrit.2012.03.014_bib154","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/35006097","article-title":"Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1","volume":"404","author":"Gu","year":"2000","journal-title":"Nature"},{"issue":"30","key":"10.1016\/j.semarthrit.2012.03.014_bib155","doi-asserted-by":"crossref","first-page":"17779","DOI":"10.1074\/jbc.271.30.17779","article-title":"Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors","volume":"271","author":"Gharaee-Kermani","year":"1996","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib156","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S","article-title":"Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis","volume":"44","author":"Distler","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib157","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.21497","article-title":"Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells","volume":"54","author":"Distler","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib158","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/bbrc.2001.4321","article-title":"Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: Differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1","volume":"281","author":"Yamamoto","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib159","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO;2-T","article-title":"Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression","volume":"44","author":"Galindo","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib160","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/art.21396","article-title":"Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: Evidence for autocrine regulation of myofibroblast differentiation","volume":"52","author":"Carulli","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.03.014_bib161","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar2766","article-title":"Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients","volume":"11","author":"Schmidt","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.03.014_bib162","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1002\/art.24049","article-title":"Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4","volume":"58","author":"Fineschi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib163","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1747.2003.12408.x","article-title":"Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma","volume":"121","author":"Yamamoto","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib164","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2005.040782","article-title":"Serum levels of monocyte chemotactic protein-3\/CCL7 are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"65","author":"Yanaba","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib166","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/art.11164","article-title":"Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse","volume":"48","author":"Ong","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib167","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4049\/jimmunol.159.3.1140","article-title":"A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha\/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes","volume":"159","author":"Hieshima","year":"1997","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib168","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/art.21257","article-title":"Serum pulmonary and activation-regulated chemokine\/CCL18 levels in patients with systemic sclerosis: A sensitive indicator of active pulmonary fibrosis","volume":"52","author":"Kodera","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib169","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/art.22559","article-title":"CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis","volume":"56","author":"Prasse","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib170","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1165\/rcmb.2003-0078OC","article-title":"Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts","volume":"29","author":"Atamas","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.03.014_bib171","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/art.21950","article-title":"Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18","volume":"54","author":"Luzina","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib172","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jcp.20452","article-title":"CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity","volume":"206","author":"Luzina","year":"2006","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.03.014_bib173","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4049\/jimmunol.160.3.1411","article-title":"Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern","volume":"160","author":"Kodelja","year":"1998","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.03.014_bib174","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ni.2109","article-title":"Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils","volume":"12","author":"Galli","year":"2011","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1165\/ajrcmb.26.5.4683","article-title":"Gene expression in bronchoalveolar lavage cells from scleroderma patients","volume":"26","author":"Luzina","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib176","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/art.22047","article-title":"Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications","volume":"54","author":"Cipriani","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.03.014_bib177","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.22698","article-title":"Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis","volume":"56","author":"Cipriani","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib178","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/keh625","article-title":"Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis","volume":"44","author":"Hayakawa","year":"2005","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib179","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/ar3242","article-title":"Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis","volume":"13","author":"Rabquer","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ard.2003.018705","article-title":"Up regulated expression of fractalkine\/CX3CL1 and CX3CR1 in patients with systemic sclerosis","volume":"64","author":"Hasegawa","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib181","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2741\/2955","article-title":"The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis","volume":"13","author":"Hasegawa","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib182","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.1780340913","article-title":"Expression and function of surface antigens on scleroderma fibroblasts","volume":"34","author":"Abraham","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.03.014_bib183","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2362.1988.tb01158.x","article-title":"Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization","volume":"18","author":"Scharffetter","year":"1988","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib184","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4049\/jimmunol.179.1.698","article-title":"Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice","volume":"179","author":"Matsushita","year":"2007","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.03.014_bib185","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/rheumatology\/kep091","article-title":"The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1","volume":"48","author":"Rabquer","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib186","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2008.102624","article-title":"Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion","volume":"69","author":"Hou","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.03.014_bib187","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/art.24435","article-title":"Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes","volume":"60","author":"Luzina","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.03.014_bib188","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1002\/art.21246","article-title":"Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts","volume":"52","author":"Asano","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.03.014_bib189","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","article-title":"Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation","volume":"177","author":"Horan","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T22:39:22Z","timestamp":1713911962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017212000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":189,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0049017212000881"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.014","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}